ÔçÒÒŮѸÀ×

    1. <form id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></form>
      <address id=SSjMaZxIp><nobr id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></nobr></address>

      Current Value of Holding

      $52.7M

      Shares

      906k

      % of Portfolio

      0.39%

      Average Buy Price

      $48.4

      Avg closing price
      Price range

      38 Paul Tudor Jones II General Motors Company Trades

      Paul Tudor Jones II acquired 14.5k General Motors Company shares worth $843k. That's 0.01% of their equity portfolio (1138th largest holding). The first General Motors Company trade was made in Q2 2013. Since then Paul Tudor Jones II bought shares 35 more times and sold shares on 37 occasions. The stake costed the investor $466k, netting the investor a gain of 81% so far.

      Avg closing price
      Price range
      Increased shares by 83.6% (+413k shares) Q2 2025
      Avg closing price $47.35
      Price range $42.48 - $50.46
      New holding (+494k shares) Q1 2025
      Avg closing price $49.32
      Price range $45.22 - $55.00
      Sold -62.5k shares Q3 2024
      Avg closing price $46.40
      Price range $39.95 - $49.90
      Sold 70.5% shares (-149k shares) Q2 2024
      Avg closing price $45.15
      Price range $42.37 - $48.86
      New holding (+212k shares) Q1 2024
      Avg closing price $38.75
      Price range $34.58 - $45.35
      Sold -225k shares Q4 2023
      Avg closing price $30.93
      Price range $26.65 - $36.25
      New holding (+225k shares) Q3 2023
      Avg closing price $35.53
      Price range $32.26 - $40.50
      Sold -46.9k shares Q1 2023
      Avg closing price $37.81
      Price range $33.38 - $43.17
      Increased shares by 634.2% (+40.5k shares) Q4 2022
      Avg closing price $36.96
      Price range $32.09 - $41.12
      New holding (+6.39k shares) Q3 2022
      Avg closing price $36.70
      Price range $30.87 - $42.05
      Sold -123k shares Q1 2022
      Avg closing price $49.93
      Price range $39.83 - $65.74
      New holding (+123k shares) Q4 2021
      Avg closing price $58.42
      Price range $53.13 - $64.61
      Sold -26.1k shares Q3 2020
      Avg closing price $28.10
      Price range $23.42 - $32.38
      New holding (+26.1k shares) Q2 2020
      Avg closing price $24.33
      Price range $18.04 - $30.68
      Sold -21.9k shares Q1 2020
      Avg closing price $30.54
      Price range $16.80 - $37.38
      Sold 61.2% shares (-34.5k shares) Q4 2019
      Avg closing price $36.34
      Price range $33.88 - $38.72
      New holding (+56.4k shares) Q3 2019
      Avg closing price $38.46
      Price range $35.89 - $40.88
      Sold -18.9k shares Q2 2018
      Avg closing price $39.37
      Price range $35.76 - $44.85
      Sold 69.8% shares (-43.8k shares) Q1 2018
      Avg closing price $40.56
      Price range $34.87 - $44.22
      Sold 59.7% shares (-93k shares) Q4 2017
      Avg closing price $43.38
      Price range $40.81 - $46.48

      News about General Motors Company and Paul Tudor Jones II

      1st Source Announces Promotion of Brian Duba to General Counsel and Secretary

      1st Source Announces Promotion of Brian Duba to General Counsel and Secretary

      South Bend, Indiana--(Newsfile Corp. - May 20, 2025) - 1st Source Corporation, (NASDAQ: SRCE) along with Chairman and CEO Christopher J. Murphy III are pleas...

      newsfilecorp.com newsfilecorp.com, 4 months ago
      Almonty Announces Results of Annual General and Special Meeting of Shareholders

      Almonty Announces Results of Annual General and Special Meeting of Shareholders

      TORONTO--(BUSINESS WIRE)--Almonty Industries Inc. (¡°Almonty¡± or the ¡°Company¡°) (TSX: AII) (ASX: AII) (OTCQX: ALMTF) (Frankfurt: ALI), a leading global produc...

      businesswire.com businesswire.com, 4 months ago
      Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

      Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

      TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (¡°Arch¡± or the ¡°Company¡±) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the U...

      globenewswire.com globenewswire.com, 5 months ago
      CP Group Announces 50,000-SF Lease Renewal With General Dynamics at Resource Square III in Orlando, Florida

      CP Group Announces 50,000-SF Lease Renewal With General Dynamics at Resource Square III in Orlando, Florida

      ORLANDO, Fla.--(BUSINESS WIRE)--CP Group, the largest office landlord in Florida and a prominent owner-operator of office properties throughout the Sunbelt, ...

      businesswire.com businesswire.com, 5 months ago

      Embed chart

      Easily embed the chart on your blog or website ¨C it will always update automatically!

      HoMEÔçÒÒŮѸÀ×